Clinical Trials Logo
  1. Home
  2. Immune-related Adverse Event
  3. NCT05544292

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors — RIMRA  

Immune-related Adverse Event Clinical Trial

Official title:
Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors - a Prospective Observational Study

Clinical Trial Summary

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05544292
Study type Observational
Source Diakonhjemmet Hospital
Contact Marte S Heiberg, MD, PhD
Phone 004722454086
Email marte.schrumpf@diakonsyk.no
Status Recruiting
Phase
Start date March 5, 2018
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06089967 - Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
Recruiting NCT05799898 - Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
Not yet recruiting NCT06278857 - SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Phase 2
Recruiting NCT05813418 - Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment N/A
Recruiting NCT05699915 - Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors N/A
Recruiting NCT05832606 - Food Intervention to Reduce Immunotherapy toXicity N/A
Completed NCT05934214 - EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
Recruiting NCT05700565 - Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
Recruiting NCT06243250 - Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events
Active, not recruiting NCT03948724 - Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology N/A
Recruiting NCT04305145 - Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Phase 2
Not yet recruiting NCT06037811 - Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis Phase 2
Not yet recruiting NCT05663775 - Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) Phase 2